FORE Biotherapeutics to Present at the Stifel 2024 Virtual Targeted Oncology Forum
PHILADELPHIA – April 11, 2024 – FORE Biotherapeutics today announced that the Company will be presenting at the Stifel 2024 Virtual Targeted Oncology Forum. The virtual presentation will take place on Wednesday, April 17, 2024 at 3:00-3:25 PM ET.
William Hinshaw, Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact your Stifel Financial Corporation salesperson or Argot Partners to schedule one-on-one meetings with the management team.
About FORE Biotherapeutics
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn.
Investors and Media:
Argot Partners
